Tale of the unexpected Irish Independent, Ireland - Nov 30, 2008 ... interesting class of moustache, which is all part of a fundraiser for men's health -- specifically raising awareness of depression and prostate cancer. ...
Omeopatia e rimedi naturali Liquida Magazine, Italy - ?Effects of Homeopathic Preparations on Human Prostate Cancer Growth in Cellular and Animal Models? nel quale si segnala una chiara risposta biologica al ...
Source: Google News
Recent News and Articles on the Keywords: cancer + prostate + 0.23 Related to the article below (Last Update: 8/7/2008)
INTERNATIONAL TRENDS AND PATTERNS OF PROSTATE CANCER INCIDENCE AND MORTALITY - AW Hsing, L Tsao, SS Devesa - Int. J. Cancer (Pred. Oncol.), 2000 - doi.wiley.com Page 1. INTERNATIONAL TRENDS AND PATTERNS OF PROSTATECANCER INCIDENCE AND MORTALITY ...
Mortality rates for prostatecancer in China and India were not available. ...
Fruit and Vegetable Intakes and Prostate Cancer Risk - JH Cohen, AR Kristal, JL Stanford - jnci, 2000 - jnci.oxfordjournals.org ... vegetable intake (simple summation) and 0.41 (95% CI = 0.23-0.72) for ... this study
were statistically significant protective effects on prostatecancer risk for ...
Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis - MR Engelbrecht, GJ Jager, RJ Laheij, AL Verbeek, H … - European Radiology, 2002 - Springer ... Without endorectal coil 0.58?0.23 n=27 0.54?0.11 n=29 ... The summary ROC curve for MR
imaging in prostatecancer staging (cT2 vs cT3) has a joint maximum ...
Source: Google Scholar
Prostate cancer, activated Stat5 protein can predict outcome
Researchers from Lombardi Comprehensive Cancer Center at Georgetown University found that testing for an activated Stat5 protein in prostate tumor tissue effectively predicts which men have a form of prostate cancer that may become more aggressive and life threatening.
In the Clinical Cancer Research, the researchers have reported that Stat5 protein in the nucleus of prostate cancer cells was a significant predictor of which patients would develop a worrisome recurrence years after their prostate cancer was initially treated. Stat5 is a protein that, when activated, signals cancer cells to continually grow and survive. The study investigated prostate cancer biopsies or prostate cancer tissues obtained from surgery from 357 prostate cancer patients, and matched active Stat5 levels with outcome.
Given further validation, the findings offer hope that a biomarker can be developed to help oncologists and urologists to identify patients that are more likely to have a recurring and/or eventually life-threatening prostate cancer. Specifically, these patients with potentially aggressive prostate cancer should be actively treated and closely monitored in contrast to men with less aggressive prostate cancer who may safely choose "watchful waiting," especially if they are elderly, the researchers say.
Sorting out the few aggressive prostate tumors from the many that are indolent is a problem that has plagued the treatment of prostate cancer, said Marja Nevalainen, principal investigator of the study.
" Most patients diagnosed with prostate cancer have slow-growing tumors that don't need aggressive therapy, but doctors do not have a way to identify the few men whose cancer is potentially dangerous. The result is that many patients are over-treated," she said.
" If future studies with Stat5 continue to show that it can help in predicting disease outcome, then we can test tumor biopsy samples for Stat5 and tailor treatment accordingly," Nevalainen said.
In the study, Georgetown researchers found that patients with mid-grade tumors who had high levels of activated Stat5 in their prostate cancer cells were 1.7 times more likely to experience disease progression compared to patients without activated Stat5. That corresponds to a 15-year, progression-free survival of 46 percent versus 62 percent, respectively.
" Mid-grade tumors are the most difficult to predict for the clinical outcome, said Nevalainen, " therefore, the most immediate use of Stat5 in prostate cancer as a marker would be for identification of the subgroup of mid-grade prostate cancers that are likely to progress early to androgen-independence and metastatic disease " said Nevalainen. " We feel that patients in this group who test positive for activated Stat5 should not remain treated with watchful waiting only, but should be actively and extensively treated."
When biopsy samples from all the patients in the study were analyzed and Stat5 readings were compared to their outcome, those with activated Stat5 had a progression-free survival rate of 44 percent, compared to 65 percent in patients whose cancer was free of activated Stat5.
Source: Georgetown University Medical Center, 2005
